Athos Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://athostx.com
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects
Phase 1
Completed
- Conditions
- Crohn DiseaseAutoimmune DiseasesInflammatory Bowel DiseasesUlcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Athos Therapeutics Inc
- Target Recruit Count
- 76
- Registration Number
- NCT05807971
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath